Arginase inhibition by rhaponticin increases L-arginine concentration that contributes to Ca2+-dependent eNOS activation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Although arginase primarily participates in the last reaction of the urea cycle, we have previously demonstrated that arginase II is an important cytosolic calcium regulator through spermine production in a p32-dependent manner. Here, we demonstrated that rhaponticin (RPT) is a novel medicinal-plant arginase inhibitor and investigated its mechanism of action on Ca2+-dependent endothelial nitric oxide synthase (eNOS) activation. RPT was uncompetitively inhibited for both arginases I and II prepared from mouse liver and kidney. It also inhibited arginase activity in both aorta and human umbilical vein endothelial cells (HUVECs). Using both microscope and FACS analyses, RPT treatments induced increases in cytosolic Ca2+ levels using Fluo-4 AM as a calcium indicator. Increased cytosolic Ca2+ elicited the phosphorylations of both CaMKII and eNOS Ser1177 in a time-dependent manner. RPT incubations also increased intracellular L-arginine (L-Arg) levels and activated the CaMKII/AMPK/Akt/eNOS signaling cascade in HUVECs. Treatment of L-Arg and ABH, arginase inhibitor, increased intracellular Ca2+ concentrations and activated CaMKII-dependent eNOS activation in ECs of WT mice, but, the effects were not observed in ECs of inositol triphosphate receptor type 1 knockout (IP3R1-/-) mice. In the aortic endothelium of WT mice, RPT also augmented nitric oxide (NO) production and attenuated reactive oxygen species (ROS) generation. In a vascular tension assay using RPT-treated aortic tissue, cumulative vasorelaxant responses to acetylcholine (Ach) were enhanced, and phenylephrine (PE)-dependent vasoconstrictive responses were retarded, although sodium nitroprusside and KCl responses were not different. In this study, we present a novel mechanism for RPT, as an arginase inhibitor, to increase cytosolic Ca2+ concentration in a L-Arg-dependent manner and enhance endothelial function through eNOS activation.
Abstract
Although arginase primarily participates in the last reaction of the urea cycle, we have previously demonstrated that arginase II is an important cytosolic calcium regulator through spermine production in a p32-dependent manner. Here, we demonstrated that rhaponticin (RPT) is a novel medicinal-plant arginase inhibitor and investigated its mechanism of action on Ca2+-dependent endothelial nitric oxide synthase (eNOS) activation. RPT was uncompetitively inhibited for both arginases I and II prepared from mouse liver and kidney. It also inhibited arginase activity in both aorta and human umbilical vein endothelial cells (HUVECs). Using both microscope and FACS analyses, RPT treatments induced increases in cytosolic Ca2+ levels using Fluo-4 AM as a calcium indicator. Increased cytosolic Ca2+ elicited the phosphorylations of both CaMKII and eNOS Ser1177 in a time-dependent manner. RPT incubations also increased intracellular L-arginine (L-Arg) levels and activated the CaMKII/AMPK/Akt/eNOS signaling cascade in HUVECs. Treatment of L-Arg and ABH, arginase inhibitor, increased intracellular Ca2+ concentrations and activated CaMKII-dependent eNOS activation in ECs of WT mice, but, the effects were not observed in ECs of inositol triphosphate receptor type 1 knockout (IP3R1-/-) mice. In the aortic endothelium of WT mice, RPT also augmented nitric oxide (NO) production and attenuated reactive oxygen species (ROS) generation. In a vascular tension assay using RPT-treated aortic tissue, cumulative vasorelaxant responses to acetylcholine (Ach) were enhanced, and phenylephrine (PE)-dependent vasoconstrictive responses were retarded, although sodium nitroprusside and KCl responses were not different. In this study, we present a novel mechanism for RPT, as an arginase inhibitor, to increase cytosolic Ca2+ concentration in a L-Arg-dependent manner and enhance endothelial function through eNOS activation.
참고문헌 (21)
- Ignarro LJ, "Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation", Proc Natl Acad Sci U S A, 98, pp.4202~4208 (2001)
- Li H, "Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells", Am J Physiol Endocrinol Metab, 280, pp.E75~E82 (2001)
- Berkowitz DE, "Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels", Circulation, 108, pp.2000~2006 (2003)
- Hein TW, "Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles : counteracting role of arginase", FASEB J, 17, pp.2328~2330 (2003)
- Jung C, "Arginase inhibition mediates cardioprotection during ischaemia-reperfusion", Cardiovasc Res, 85, pp.147~154 (2010)
- Johnson FK, "Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension", Am J Physiol Regul Integr Comp Physiol, 288, pp.R1057~R1062 (2005)
- Zhang C, "Upregulation of vascular arginase in hypertension decreases nitric oxidemediated dilation of coronary arterioles", Hypertension, 44, pp.935~943 (2004)
- Peyton KJ, "Arginase promotes neointima formation in rat injured carotid arteries", Arterioscler Thromb Vasc Biol, 29, pp.488~494 (2009)
- Ryoo S, "Endothelial arginase II : a novel target for the treatment of atherosclerosis", Circ Res, 102, pp.923~932 (2008)
- Koo BH, "Arginase II contributes to the Ca(2+)", CaMKII, J Am Heart Assoc, pp.2018, 7[DOI]
- Pandey D, "OxLDL triggers retrograde translocation of arginase2 in aortic endothelial cells via ROCK and mitochondrial processing peptidase", Circ Res, 115, pp.450~459 (2014)
- Koo BH, "p32-Dependent p38 MAPK activation by arginase II downregulation contributes to endothelial nitric oxide synthase activation in HUVECs", Cells, 9, pp.392~ (2020)
- Fleming I, "Phosphorylation of Thr(495)regulates Ca(2+)", calmodulin-dependent endothelial nitric oxide synthase activity, 2001, pp.88, E68~E75
- Salerno JC, "An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase", J Biol Chem, 272, pp.29769~29777 (1997)
- Matsuda H, "Anti-allergic activity of stilbenes from Korean rhubarb(Rheum undulatum L.) : structure requirements for inhibition of antigen-induced degranulation and their effects on the release of TNF-alpha and IL-4 in RBL-2H3cells", Bioorg Med Chem, 12, pp.4871~4876 (2004)
- Ko SK, "Anti-platelet aggregation activity of stilbene derivatives from Rheum undulatum", Arch Pharm Res, 22, pp.401~403 (1999)
- Tao L, "Protective role of rhapontin in experimental pulmonary fibrosis in vitro and in vivo", Int Immunopharmacol, 47, pp.38~46 (2017)
- Wei W, "Rhapontin ameliorates colonic epithelial dysfunction in experimental colitis through SIRT1 signaling", Int Immunopharmacol, 42, pp.185~194 (2017)
- Chen J, "Rhaponticin from rhubarb rhizomes alleviates liver steatosis and improves blood glucose and lipid profiles in KK", Ay diabetic mice, 2009, pp.75, 472~477
- Topal G, "Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells", J Pharmacol Exp Ther, 318, pp.1368~1374 (2006)
- Solomonson LP, "The caveolar nitric oxide synthase", arginine regeneration system for NO production in endothelial cells, 2003, pp.206, 2083~2087